Cause and Importance of the Age-dependent Sarcopenia

NCT02994901 | Completed

• 1 other identifier: EA1/260/16
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this cross-sectional study is to evaluate the difference in cytokine profiling approach and mitochondrial function between geriatric sarcopenic patients (group 1) and geriatric non-sarcopenic patients (group 2) and healthy (group 3) geriatric participants.

Conditions

Sarcopenia

Keywords

Sarcopenia; Geriatrics; Biomarker

Outcome Measures

Primary Outcomes (1)

• Differences in mitochondrial respiratory capacity of peripheral blood mononuclear cells (PBMCs) using Oxygraph-2k respirometry

  Baseline

Secondary Outcomes (3)

• Quality of life (validated questionnaire)

  Baseline

• Frailty Status according to Fried et.al. criteria

  Baseline

• Functional limitations (single validated questionnaire)

  Baseline

Study Arms (3)

Group 1

Geriatric patient with Sarcopenia

Group 2

Geriatric Patient without Sarcopenia

Group 3

healthy control group

Eligibility Criteria

• Age: 60 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Group 1: sarcopenic patient Group 2: non-sarcopenic patient Group 3: healthy control

You may qualify if:

• Age between 60 and 85 years
• Informed written consent
• Normal cognitive status according to Mini-Mental State Examination (MMSE ≥ 24 points)
• Life expectancy of \> 3 months according to treating doctor
• without implanted Defibrillation
• without acute Sepsis
• without neurodegenerative diseases, especially amyotrophic lateral sclerosis (ALS) and Huntington

You may not qualify if:

• Age \< 60 years or \> 85 years
• Lack of informed written consent
• Low cognitive status according to Mini-Mental State Examination (MMSE \< 24 points)
• Life expectancy of \< 3 months according to treating doctor
• Implanted Defibrillation
• Acute Sepsis
• neurodegenerative diseases, especially amyotrophic lateral sclerosis (ALS) and Huntington

Sponsors & Collaborators

• Charite University, Berlin, Germany: lead
• German Institute of Human Nutrition: collaborator

Study Sites (1)

Charite University Medicine, Research Group on Geriatrics

Berlin, 13347, Germany

Location

Related Publications (2)

• Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, Leeuwenburgh C. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol. 2013 Oct;45(10):2288-301. doi: 10.1016/j.biocel.2013.06.024. Epub 2013 Jul 8.

  PMID: 23845738 BACKGROUND

• Leger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008 Feb;11(1):163-175B. doi: 10.1089/rej.2007.0588.

  PMID: 18240972 BACKGROUND

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Kristina Norman, PD Dr.

  Charite Research Group on Geriatrics

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PD Dr.

Study Record Dates

• First Submitted: December 7, 2016
• First Posted: December 16, 2016
• Study Start: November 1, 2016
• Primary Completion: June 1, 2017
• Study Completion: July 30, 2017
• Last Updated: January 28, 2020

Record last verified: 2020-01

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)